Literature DB >> 2703539

Bulky extramedullary plasmacytomata: rare mode of relapse in myelomatosis.

S V Davies1, B Jones, C M Starkie, J A Murray.   

Abstract

In two cases of myelomatosis relapse was accompanied by the development of bulky extramedullary plasma cell tumours, which created serious management problems. In both cases the histology was of a poorly differentiated plasmacytoid tumour with frequent mitoses. In one case paraprotein had completely disappeared from the serum and urine after six months' treatment with melphalan alone but did not correlate with improved survival. It is concluded that extramedullary spread of myelomatosis in the form of bulky tumour deposits is a rare and ominous mode of tumour progression or relapse. Rises in serum and urinary paraprotein concentrations are not the inevitable signs of relapse.

Entities:  

Mesh:

Year:  1989        PMID: 2703539      PMCID: PMC1141862          DOI: 10.1136/jcp.42.3.246

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Extramedullary lesions in multiple myeloma; review of literature and pathologic studies.

Authors:  D W HAYES; W A BENNETT; F J HECK
Journal:  AMA Arch Pathol       Date:  1952-03

2.  Results of the MRC myelomatosis trials for patients entered since 1980.

Authors:  I C MacLennan; K Kelly; R A Crockson; E H Cooper; J Cuzick; C Chapman
Journal:  Hematol Oncol       Date:  1988 Apr-Jun       Impact factor: 5.271

Review 3.  The current status and future prospects of treatment for multiple myeloma.

Authors:  B G Durie; S E Salmon
Journal:  Clin Haematol       Date:  1982-02

Review 4.  Localized Plasmacytomas.

Authors:  R Bataille
Journal:  Clin Haematol       Date:  1982-02

5.  IgD multiple myeloma. Review of 133 cases.

Authors:  Z Jancelewicz; K Takatsuki; S Sugai; W Pruzanski
Journal:  Arch Intern Med       Date:  1975-01

6.  Aggressive plasma cell myeloma. A terminal phase.

Authors:  A L Suchman; M Coleman; J A Mouradian; D J Wolf; S Saletan
Journal:  Arch Intern Med       Date:  1981-09

7.  Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.

Authors:  R Bataille; J Grenier; J Sany
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

8.  Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

Authors:  B G Durie; S E Salmon; T E Moon
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

9.  Anaplastic myeloma with massive extramedullary involvement. Report of two cases.

Authors:  K Foucar; M Raber; E Foucar; B Barlogie; C M Sandler; R Alexanian
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

  9 in total
  2 in total

1.  Extramedullary gastric plasmacytoma.

Authors:  J W Hamilton; W G McCluggage; F Jones; J Collins
Journal:  Ulster Med J       Date:  1999-11

2.  Relapsed Extramedullary Multiple Myeloma Presenting as Bilateral Solid Perirenal Masses.

Authors:  Thomas Rau; Aya Kamaya
Journal:  Radiol Case Rep       Date:  2015-12-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.